A major challenge in cancer therapy is the destruction of undetectable micrometastases that persist after tumor resection/ablation. In many patients, indeed, these micrometastases eventually develop into lethal lesions. A lasting protection against micrometastases may be achieved by immunotherapy, promoting the activation of the immune system against the one or many autologous tumor-associated antigens (TAAs). The immune system is capable of protecting against tumor cells presenting TAAs, as it can be inferred from the correlation between the extent of T-cell infiltration observed in resected tumors and patient survival. 1, 2 Many TAAs are unique to each cancer patient and are generated by coding mutations, owing to genomic instability. 3 The identification of autologous TAAs on an individual basis and their synthesis for vaccination purposes are not feasible at present. Therefore, the tumor itself is a practical source for vaccinating patients with autologous TAAs. An effective immunization by TAAs expressed by autologous tumor cells requires the uptake of these cells (or their debris) by antigenpresenting cells (APCs), which present
In situ conversion of tumors into autologous tumor-associated antigen vaccines by intratumoral injection of α-gal glycolipids TAA-derived peptides on MHC molecules for activating tumor-specific T cells. In many patients, tumors evolve strategies to evade recognition and uptake by APCs. Thus, tumors are often "ignored" by the immune system and micrometastases can reside and proliferate in lymph nodes. Effective tumor vaccines require both the recruitment of APCs into the tumor and the active targeting of tumor cells for uptake by APCs.
We have developed an immunotherapeutic regimen that promotes the recruitment of APCs into the tumor and in situ targets tumor cells for uptake by APCs, based on the intratumoral injection of α-gal glycolipids that interact with the natural anti-Gal antibody. 4, 5 Anti-Gal is the most abundant antibody in humans, constituting ~1% of immunoglobulins. 6 Its ligand, the α-gal epitopes (Galα1-3Galβ1-4GlcNAc-R), is absent in humans and is produced in nonprimate mammals by the glycosylation enzyme α1,3-galactosyltransferase (α1,3GT). 7, 8 The anti-Gal antibody interacts very effectively in vivo with α-gal epitopes and activates the complement system, as indicated by the rapid rejection of pig xenografts following anti-Gal binding to α-gal epitopes on pig cells. 9 Tumor cells can be manipulated to express α-gal epitopes by the intratumoral injection of α-gal glycolipids, hence becoming a target for anti-Gal antibodies. α-Gal glycolipids present linear or branched carbohydrate chains capped by α-gal epitopes. 4, 7 These glycolipids are extracted in large amounts from rabbit red cell membranes and dissolve in water as micelles. When injected into tumors, α-gal glycolipids insert into tumor cell membranes because their hydrophobic lipid "tail" is energetically much more stable when surrounded by cell membrane phospholipids than in micelles within aqueous environments (Fig. 1A) . This spontaneous process results in the presentation of multiple α-gal epitopes on tumor cells.
In vitro studies indicate that the incubation of tumor cells lacking α-gal epitopes with 0.1 or 1 mg/mL α-gal glycolipids results in their extensive insertion into tumor cell membranes and cytolysis of these cells in the presence of anti-Gal antibodies and complement. 4, 5, 10 The in vivo effects of α-gal glycolipids injected intratumorally were studied in a preclinical the immunogenicity of autologous tumor-associated antigens (tAAs) is markedly increased upon the intratumoral injection of α-gal glycolipids, which insert into tumor cell membranes. the binding of natural anti-Gal antibodies to these glycolipids activates the complement system and recruits antigen-presenting cells (APCs), which internalize antiGal-coated tumor cells upon Fc/Fcγr interactions. eventually, tAA-derived peptides presented by APCs activate a t cellmediated tumor-specific immune response.
The antitumor immune response elicited by the intratumoral injection of α-gal glycolipids appears to be primarily mediated by CD8 + T cells and to be potent enough to overcome the immunosuppressive effect of regulatory T cells. 5 The safety of α-gal glycolipids as an immunotherapeutic intervention was evaluated in a Phase I clinical trial in patients bearing various malignant solid tumors at an advanced stage of the disease. 10 Patients received intratumorally 0.1 mg, 1 mg, or 10 mg α-gal glycolipids and kept under observation for 24 h. Subsequently, patients were monitored at regular intervals. None of the patients developed clinical or laboratory signs of toxicity, symptoms of allergic responses, autoimmune conditions, anti-nuclear antibodies or autoantibodies to normal tissue antigens. 10 Thus, the treatment does not seem to cause a breakdown in immune tolerance to normal antigens. Injected tumors did not regress and patients developed evidence of disease progression at various time points after the four-week endpoint. However, several patients are alive with disease for 13+ to 48+ months, even though disease progression is evident by imaging. In addition, two patients with pancreatic adenocarcinoma had an unexpectedly long survival of 18 and 23 mo. 10 The therapeutic effect of intratumoral α-gal glycolipids injection may not be limited to advanced diseases, but may improve outcome also when used as neoadjuvant immunotherapy. Injection of primary solid tumors such as colon or mammary carcinoma 2-4 weeks prior to resection may convert treated lesion into a temporary vaccine that "educates" the immune system to recognize and destroy metastatic cells presenting autologous TAAs. Such an induced immunosurveillance may protect against micrometastases long after the primary tumor is resected. This immunotherapeutic approach may synergize with treatments that nonspecifically expand the tumor-specific T-cell clones that are activated following the injection of α-gal glycolipids.
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including dendritic cells and macrophages, within treated tumors. 4 As a result, the Fc portion of anti-Gal antibodies coating tumor cells interacted with Fcγ receptors on APCs and stimulated them to internalize tumor cells, process TAAs and present TAA-derived peptides to tumor-specific T cells (Fig. 1B) . These T cells mediated a systemic protective antitumor immune response that prevented tumor growth upon challenge at distant sites as well as the growth of established micrometastates. 4, 5 model involving α1,3GT deficient mice producing anti-Gal antibodies and carrying B16 melanoma tumors (which naturally lack α-gal epitopes). Injections of α-gal glycolipids into melanoma lesions resulted in tumor regression following complement-mediated cytolysis and antibody-dependent cell-mediated cytotoxicity (ADCC). 4 The complement-derived chemotactic factors generated upon anti-Gal/α-gal glycolipid interactions induced an extensive recruitment of APCs, APCs transport internalized tAAs to regional lymph nodes, process them and present the multiple autologous and potentially immunogenic tAA-derived peptides in association with MhC Class I and Class II molecules for the activation of tAA-specific t CD8 + and CD4 + cells, respectively. these activated t cells mediate a protective antitumor immune response.
